康缘药业：部分董事、高级管理人员拟合计不低于12万股股份

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) announced a share buyback plan by its executives, reflecting confidence in the company's future development and long-term investment value [1] Group 1: Share Buyback Plan - The company's executives, including the general manager and several board members, plan to increase their holdings by no less than 120,000 shares within one month from the announcement date [1] - The shares to be purchased are part of the restricted stock incentive plan granted in 2022 [1] - The buyback will not have a set price range and will be executed based on stock price fluctuations and overall market trends [1]